NL-OMON33835已完成不适用
89Zr-bevacizumab labelled PET imaging in patients with Renal Cell Carcinoma treated with sunitinib or bevacizumab plus interferon; a pilot study - VEGF imaging in Renal Cell Carcinoma
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational invasive
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •locally advanced irresectable or metastatic renal cell cancer
- •no untreated brain metastases (CT or MRI not necessary in the absence of symptoms)
- •no uncontrolled hypertension
- •no clinically significant cardiovascular events or disease during the last 12 months
- •no surgery in the last 4 weeks
- •no treatment with bevacizumab or another monoclonal antibody with anti-angiogenic properties in the last 4 months
- •no treatment with a tyrosine kinase inhibitor during the last 4 weeks
- •measurable disease with x-ray or CT scan, at least one site of disease must be unidimensionally measurable as follows:
- •X ray >= 20 mm
- •Spiral CT scan >= 10 mm
- •Non-spiral CT scan >= 20 mm
- •>= 18 years
- •clear cell histology component
- •absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
- •before patient randomization, written informed consent must be given according to GCP, and local regulations
排除标准
- •Are formulated as no existence of in inclusion criteria
研究者
相似试验
已完成
不适用
Everolimage. 89Zr-bevacizumab PET imaging in patients with Renal Cell Carcinoma treated with everolimus; a pilot study.kidney cancer1003836310038430renal cell carcinomaNL-OMON36512niversitair Medisch Centrum Groningen14
已完成
不适用
89Zr-bevacizumab PET imaging as predictive biomarker for everolimus efficacy in patients with neuroendocrine tumorshormone producing cancerneuroendocrine tumors10014713NL-OMON32849niversitair Medisch Centrum Groningen14
招募中
2 期
89Zr-Bevacizumab PET/CT imaging of vestibular schwannomas for the prediction of bevacizumab treatment effect in patients with symptomatic neurofibromatosis type 2.hereditary tumor syndrome1002239610029209NFNL-OMON52411eids Universitair Medisch Centrum24
进行中（未招募）
1 期
89Zr-Bevacizumab PET/CT imaging of vestibular schwannomas for the prediction of bevacizumab treatment effect in patients with symptomatic neurofibromatosis type 2.eurofibromatosis type 2EUCTR2020-000156-35-NLeiden University Medical Center15
已完成
不适用
89Zr-pembrolizumab-PET imaging in patients with locally advanced or metastatic melanoma or non-small cell lung cancerMelanoma and non-small cell lung cancer1004090010029107NL-OMON43013niversitair Medisch Centrum Groningen21